John E. Kao, chief executive officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold a combined 250,000 shares of common stock on April 7, 2026, in two separate transactions that together totaled about $5.25 million.
The first block consisted of 132,241 shares transacted at a weighted-average price of $20.67, yielding proceeds of $2,733,314. Reported trade prices for that tranche ranged from $20.18 to $21.17. The second block comprised 117,759 shares sold at a weighted-average price of $21.3953, producing proceeds of $2,519,596. Prices for the second tranche ranged between $21.18 and $21.56.
Those shares were sold indirectly from holdings in the JEK Trust, dated February 8, 2021, for which Kao serves as trustee. After the April 7 transactions, Kao is recorded as indirectly holding 2,104,641 shares and directly holding 1,784,868 shares of Alignment Healthcare common stock.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan that Kao adopted on November 21, 2025.
Market context and valuation signals
The insider sale coincided with a recent rally in ALHC shares. The stock has risen approximately 19.5% over the last week and was trading at $21.31 at the time of reporting. According to InvestingPro analysis, ALHC now appears slightly overvalued relative to its Fair Value estimate and is listed among companies on the Most Overvalued list. InvestingPro also notes that a detailed examination is available through ALHC’s Pro Research Report, which is one of more than 1,400 US equity reports on the platform.
Company results, analyst views and capital markets activity
Alignment Healthcare recently released fourth-quarter results that the company characterized as strong. Reported metrics included a 25% year-over-year increase in membership and a 44.4% rise in revenue, both of which exceeded expectations. The company achieved a medical benefit ratio of 87.7%, while its selling, general and administrative expense ratio improved by roughly 115 basis points to 9.7%.
Following those results, Raymond James reiterated a Strong Buy rating with a $27.00 price target, and Piper Sandler maintained an Overweight rating with a $30.00 price target.
Separately, Alignment Healthcare disclosed the pricing of a secondary offering by an affiliate of General Atlantic, L.P. The offering totals 13.2 million shares priced at $19.46 per share. Alignment Healthcare stated it will not receive any proceeds from that sale. The offering is expected to close on March 4, 2026, subject to customary closing conditions, with J.P. Morgan serving as underwriter.
These developments - the CEO's stock sale under a 10b5-1 plan, recent quarterly outperformance, analyst endorsements and a sizable secondary sale by a large shareholder affiliate - together sketch the current set of corporate and market events shaping investor interest in Alignment Healthcare.